Letrozol Almus

Letrozole, the active ingredient in Letrozol Almus, is an aromatase inhibitor presented as an oral tablet for systemic use. It is employed to lower estrogen levels and is indicated for the treatment of hormone receptor‑positive breast cancer in postmenopausal women. The drug is administered orally once daily under medical supervision.

GNH USA supplies Letrozol Almus as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, adhering to EU GMP standards and providing full traceability from manufacturing to delivery.

Letrozol Almus acts on estrogen‑dependent breast cancer pathways and is used in several clinical settings.

- Postmenopausal hormone receptor‑positive breast cancer: reduces tumor growth by lowering estrogen levels. - Adjuvant therapy for early‑stage breast cancer: decreases risk of recurrence after surgery. - Metastatic breast cancer: helps control disease progression in estrogen‑dependent tumors.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: aching in joints or muscles. - Fatigue: persistent tiredness not relieved by rest. - Nausea: upset stomach, sometimes with vomiting. - Headache: mild to moderate head pain. - Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects: - Severe liver injury: jaundice, dark urine, abdominal pain. - Bone fracture: increased risk due to reduced estrogen. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Cardiovascular events: hypertension or cardiac arrhythmia. - Severe allergic reaction: rash, swelling, difficulty breathing.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor for potential complications.

- Monitor liver function: check hepatic enzymes periodically. - Assess bone health: consider calcium and vitamin D supplementation and bone density testing. - Contraindicated in pregnancy: category X, avoid exposure in women of childbearing potential. - Review concomitant medications: evaluate for possible drug‑drug interactions. - Educate on thromboembolic signs: advise patients to seek immediate care for leg swelling or chest pain. - Store at ambient temperature: keep in original container, protect from moisture and light.

Letrozole can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Tamoxifen: concurrent use may reduce the effectiveness of both agents. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower letrozole plasma concentrations. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase letrozole exposure and risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: letrozole may affect INR; monitor coagulation parameters. - SSRIs (e.g., fluoxetine, paroxetine): potential alteration of metabolism; observe for side‑effects. - Statins: monitor for changes in lipid levels and muscle symptoms.